OncoMatch/Clinical Trials/NCT06577194
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
Is NCT06577194 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sintilimab + IL-2 Combined with CAPOX for rectal cancer.
Treatment: Sintilimab + IL-2 Combined with CAPOX — A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy with IL-2 Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Tumor Agnostic
Disease stage
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anti-cancer treatment
Previous systemic anti-cancer treatment for colorectal cancer
Cannot have received: anti-PD-1 therapy
Previous treatment with anti-programmed death receptor-1 (PD-1) or its ligand (PD-L1) antibodies
Cannot have received: anti-PD-L1 therapy
Previous treatment with anti-programmed death receptor-1 (PD-1) or its ligand (PD-L1) antibodies
Cannot have received: anti-CTLA-4 therapy
Previous treatment with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies
Lab requirements
Blood counts
neutrophil count ≥ 1.5×10^9/L; platelet count ≥ 75×10^9/L
Kidney function
serum creatinine ≤ 1.5× UNL
Liver function
serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL
Adequate hematological, liver, and kidney functions: neutrophil count ≥ 1.5×10^9/L; platelet count ≥ 75×10^9/L; serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL; serum creatinine ≤ 1.5× UNL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06577194 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages